

BIOCON BIOLOGICS SPAIN S.L.U
BALANCE SHEET AS AT MARCH 31, 2026

(All amounts in EUR Thousands, except share data and unless otherwise stated)

	<u>Notes</u>	March 31, 2026	March 31, 2025
ASSETS			
Non-current assets			
Deferred tax asset (net)		6	-
Total non-current assets		6	-
Current assets			
Inventories	1	3,092	2,583
Financial assets			
(i) Trade receivables	2	1,392	2,049
(ii) Cash and cash equivalents	3	1,580	602
Other current assets	4	6	6
Total current assets		6,070	5,240
TOTAL		6,076	5,240
EQUITY AND LIABILITIES			
Equity			
Equity share capital	5	3	3
Other equity	6	296	174
Total equity		299	177
Current liabilities			
Financial liabilities			
Trade payables	7	5,660	4,918
Income-tax liability (net)		30	47
Provisions	8	65	30
Other current liabilities	9	22	68
Total current liabilities		5,777	5,063
TOTAL		6,076	5,240

BIOCON BIOLOGICS SPAIN S.L.U**STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED MARCH 31, 2026**

(All amounts in EUR Thousands, except share data and unless otherwise stated)

		Year ended March 31, 2026	Year ended March 31, 2025
	<u>Notes</u>		
Income			
Revenue from operations	10	8,032	9,606
Other operating income	11	(35)	-
Total revenue		7,997	9,606
Expenses			
Purchases of traded goods	12	5,431	5,235
Changes in inventories of traded goods	13	(509)	1,417
Employee benefits expense	14	2,176	1,372
Other expenses	15	720	1,394
Total expenses		7,818	9,418
Profit/(loss) before exceptional item and tax		179	188
Exceptional items		10	-
Profit/(loss) before tax		169	188
Tax expense			
Current tax		50	42
Deferred Tax		(6)	5
Total tax expense		44	47
Profit for the period		125	141

BIOCON BIOLOGICS SPAIN S.L.U
STATEMENT OF CASH FLOWS FOR THE YEAR ENDED MARCH 31, 2026

(All amounts in EUR Thousands, except share data and unless otherwise stated)

	Year ended March 31, 2026	Year ended March 31, 2025
I Cash flows from operating activities		
Profit after tax	125	141
<u>Adjustments to reconcile profit before tax to net cash flows:</u>		
Unrealised foreign exchange loss	35	-
Tax expense	44	47
Operating profit before working capital changes	204	188
Movements in working capital		
Decrease/(Increase) in trade receivables	622	(1,176)
(Increase)/Decrease in trade inventories	(509)	1,417
Increase/(Decrease) in trade payable, other liabilities and provisions	729	(1,393)
Cash generated from/ (used in) operations	1,046	(964)
Direct taxes paid	(68)	(16)
Net cash flow generated from/(used in) operating activities	978	(980)
II Cash flows from investing activities		
Net cash flow generated from investing activities	-	-
III Cash flows from financing activities		
Net cash flow generated from financing activities	-	-
IV Net increase/(decrease) in cash and cash equivalents (I + II + III)	978	(980)
V Effect of exchange differences on cash and cash equivalents held in foreign currency	-	-
VI Cash and cash equivalents at the beginning of the year	602	1,582
VIII Cash and cash equivalents at the end of the year (IV + V + VI)	1,580	602
Reconciliation of cash and cash equivalents as per statement of cash flow		
Cash and cash equivalents		
Balances with banks - on current accounts	65	602
- on deposit accounts	1,515	-
Cash on hand	-	-
Total cash and cash equivalents [Refer note 3]	1,580	602

BIOCON BIOLOGICS SPAIN S.L.U**Notes to financial statements for the year ended March 31, 2026**

(All amounts in EUR Thousands, except share data and unless otherwise stated)

	March 31, 2026	March 31, 2025
1. Inventories		
Finished Goods	3,092	2,583
	3,092	2,583
2. Trade receivables		
Unsecured, considered good	1,433	2,049
Allowance for credit loss	(41)	-
	1,392	2,049
3. Cash and cash equivalents		
Balances with banks:		
On current accounts	65	602
Deposit accounts	1,515	-
	1,580	602
4. Other current assets		
Advance to suppliers	6	6
	6	6
5. Share capital		
3,000 Equity shares of EUR 1 each	3	3
	3	3
6. Other equity		
Surplus in the statement of profit and loss		
Balance as per the last financial statements	171	33
Profit for the period	125	141
Net surplus in the statement of profit and loss	296	174
Total other equity	296	174
7. Trade payables	5,660	4,918
8. Provisions		
Current		
Compensated absences	65	30
	65	30
9. Other liabilities		
Current liabilities		
Statutory liabilities	22	68
Conveyance Exp Staff	-	-
	22	68

BIOCON BIOLOGICS SPAIN S.L.U**Notes to financial statements for the year ended March 31, 2026**

(All amounts in EUR Thousands, except share data and unless otherwise stated)

	Year ended March 31, 2026	Year ended March 31, 2025
10. Revenue from operations		
Sale of Products		
Traded Goods	7,875	9,417
Sale of Services		
Support service cross charge to Group Companies	157	189
	8,032	9,606
11. Other operating income		
Foreign exchange fluctuations, net	(47)	-
Interest income	12	-
	(35)	-
12. Purchase of traded goods	5,431	5,235
13. Changes in inventories of traded goods		
Inventory at the beginning of the year		
Traded goods	2,583	4,000
Inventory at the end of the year		
Traded goods	3,092	2,583
	(509)	1,417
14. Employee benefits expense		
Salaries, wages and bonus	2,160	1,367
Employee stock compensation expense	16	4
Staff welfare expenses	-	1
	2,176	1,372
15. Other expenses		
Rates and taxes	15	4
Rent	89	58
Legal and professional fees	141	709
Repair and Maintenance	1	-
Travelling and conveyance	143	171
Selling expenses	116	97
Sales promotion expenses	95	279
Printing and stationery	(7)	39
Communication expenses	6	4
Miscellaneous expenses	53	26
Insurance Charges	27	7
Provision/(reversal) for doubtful debts, net	41	-
	720	1,394